TLX NASDAQ
Telix Pharmaceuticals Limited
1W: -7.9%
1M: -7.9%
3M: -13.2%
YTD: +38.5%
1Y: +3.7%
$10.55
-0.17 (-1.59%)
Weekly Expected Move ±10.7%
$8
$9
$11
$12
$13
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$26M
-160.3% ▼
Capital Expenditures
$57M
-297.0% ▼
5Y CAGR: +181.4%
Free Cash Flow
-$83M
-388.4% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$446M
-176.0% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$81M | -$104M | $5M | $0 | -$11M |
| Depreciation & Amort. | $5M | $5M | $7M | $0 | $33M |
| Stock-Based Comp. | $1M | $8M | $9M | $0 | $0 |
| Change in Working Capital | -$3M | -$1M | -$58M | -$64M | -$68M |
| Other Non-Cash Items | $32M | $41M | $60M | $107M | $20M |
| Operating Cash Flow | -$59M | -$64M | $24M | $43M | -$26M |
| — Investing Activities — | |||||
| Capital Expenditures | -$1M | -$14M | -$10M | -$14M | -$84M |
| Acquisitions (Net) | $0 | -$973K | -$1M | -$35M | -$331M |
| Investment Purchases | $0 | $0 | -$13M | -$52M | -$1M |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | -$1M | -$2M | -$1M | -$34M | -$13M |
| Investing Cash Flow | -$3M | -$17M | -$25M | -$135M | -$429M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$340K | $3M | $6M | $653M | -$435K |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$596K | -$1M | -$2M | -$15M | -$8M |
| Financing Cash Flow | $3M | $175M | $10M | $639M | -$6M |
| Net Change in Cash | -$56M | $94M | $7M | $587M | -$446M |
| Cash End of Period | $22M | $116M | $123M | $710M | $213M |
| Free Cash Flow | -$61M | -$78M | $13M | $9M | -$83M |